A recent study showed that a novel DHODH inhibitor AG636 induced potent anti-AML as well as anti-LSC effects with limited effects on normal hematopoiesis in preclinical model of MLL-AF9 AML. Here, KMT2A is linked to acute myeloid leukemia.